Head-to-head evidence
Lipovirtide vs LP-98
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV gp41 · full HIV pipeline
Lipovirtide
Developed by Shanxi Kangbao Biological Product
NCT06061536 · Phase 2 · completed
The study was randomized and included an active DTG comparator, but it was open-label, enrolled 64 participants across four groups, and used viral suppression as a surrogate laboratory endpoint rather than a hard clinical outcome. Because the primary comparison and its statistical result are not available, the findings cannot be judged as having met or missed the endpoint.
LP-98
Developed by Shanxi Kangbao Biological Product
NCT06560489 · Phase 1/2 · completed
The study randomly assigned 40 participants to four blinded LP-98 dose groups, but it did not include a placebo or active-control arm. Its primary outcomes were laboratory, vital-sign, and electrocardiographic measures rather than hard clinical outcomes, and the primary results are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lipovirtide's landscape · LP-98's landscape